Related Experiment Video
Updated: Jun 22, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole
Bulent Karagöz1, Ali Ayata, Oğuz Bilgi
1Department of Medical Oncology, GATA Haydarpaşa Training Hospital, Istanbul, Turkey. bulentkaragoz1968@yahoo.com
Background:
Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer. Anastrozole treatment is associated with a risk of thromboembolic events and retinal vascular side effects. Herein, we present a case of hemi-central retinal artery occlusion diagnosed in a breast cancer patient using anastrozole.
Case Report:
A 53-year-old woman with a hypertensive and diabetic background was admitted to our hospital with breast cancer. Anastrozole treatment was started after surgery, adjuvant chemotherapy, and radiotherapy. Sudden painless loss of vision in the patient's right eye occurred within 13 months of Anastrozole treatment. A fluorescein angiogram revealed hemi-central retinal artery occlusion.
Conclusion:
To the best knowledge of the authors, this is the first report of hemi-central retinal artery occlusion in an anastrozole user.